Mark C Genovese

Mark C Genovese

UNVERIFIED PROFILE

Are you Mark C Genovese?   Register this Author

Register author
Mark C Genovese

Mark C Genovese

Publications by authors named "Mark C Genovese"

Are you Mark C Genovese?   Register this Author

100Publications

3299Reads

28Profile Views

TNF-alpha inhibition for the treatment of cardiac sarcoidosis.

Semin Arthritis Rheum 2019 Nov 15. Epub 2019 Nov 15.

Department of Medicine, Division of Immunology and Rheumatology, Stanford University, United States; Department of Health Research and Policy, Division of Epidemiology, Stanford University, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2019.11.004DOI Listing
November 2019

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.

J Rheumatol 2019 Aug 15;46(8):887-895. Epub 2019 Jan 15.

From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.171469DOI Listing
August 2019

Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis.

J Rheumatol 2019 Jun 15. Epub 2019 Jun 15.

From the Division of Immunology and Rheumatology, Department of Pathology, Department of Surgery, Stanford University School of Medicine, Palo Alto, California, USA. A. Postolova, MD, MPH, Fellow in Allergy/Immunology/Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; M.L. Troxell, MD, PhD, Professor of Pathology, Stanford University Medical Center; I.L. Wapnir, MD, Professor of Surgery, Department of Surgery, Stanford University School of Medicine; M.C. Genovese, MD, James W. Raitt Endowed Professor of Medicine, Co-Chief, Division of Immunology and Rheumatology, Stanford University School of Medicine. Address correspondence to Dr. A. Postolova, Division of Immunology and Rheumatology, Stanford University School of Medicine, 1000 Welch Road, Suite 203, Palo Alto, California 94305, USA. E-mail: Accepted for publication June 4, 2019.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181205DOI Listing
June 2019

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.

J Rheumatol 2019 01 15;46(1):7-18. Epub 2018 Sep 15.

From the Division of Rheumatology, Department of Medicine, Medical University of Vienna, Vienna, Austria; Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California, USA; Division of Rheumatology, Department of Internal Medicine, Keio University, Tokyo, Japan; Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, USA; Lilly Research Laboratories, Eli Lilly and Co., Kobe, Japan; Oregon Health Sciences University, Portland, Oregon, USA.

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.171361
Publisher Site
http://dx.doi.org/10.3899/jrheum.171361DOI Listing
January 2019

Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis.

BMC Rheumatol 2019 31;3. Epub 2019 Jan 31.

1Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev Hovedgade 205-207, 2730 Herlev, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s41927-019-0052-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390574PMC
January 2019

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.

Rheumatology (Oxford) 2018 11;57(11):2001-2011

Department of Medicine, University of Queensland, Rheumatology Research Unit Sunshine Coast, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199530PMC
November 2018

Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.

J Rheumatol 2018 08 15;45(8):1085-1092. Epub 2018 Apr 15.

From Stanford University, Palo Alto, California; Arthritis Center of Nebraska, Lincoln, Nebraska; Box Arthritis and Rheumatology of the Carolinas, Charlotte, North Carolina; Low Country Rheumatology, Charleston, South Carolina; Bristol-Myers Squibb, Princeton, New Jersey, USA; Universidad Autónoma de Chihuahua, Chihuahua; Unidad Reumatológica Las Américas S.C.P., Mérida; Köhler & Milstein Research, Mérida, Mexico; Instituto De Ginecología Y Reproducción, Lima, Peru; Organización Médica de Investigación, Buenos Aires, Argentina; Pontifical Catholic University, Porto Alegre, Brazil; University of Queensland, Brisbane, Australia; Russian Academy of Medical Sciences, Moscow, Russia; Cliniques Universitaires Saint-Luc; Université Catholique de Louvain, Brussels, Belgium; Schlosspark-Klinik University Medicine, Berlin, Germany.

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.170344
Publisher Site
http://dx.doi.org/10.3899/jrheum.170344DOI Listing
August 2018

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.

J Rheumatol 2018 01 15;45(1):14-21. Epub 2017 Aug 15.

Kennedy Institute of Rheumatology and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.161161DOI Listing
January 2018

Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.

Ann Rheum Dis 2017 Jun 22;76(6):1078-1085. Epub 2016 Dec 22.

Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2016-210297DOI Listing
June 2017

Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings.

Ann Rheum Dis 2016 Nov 15;75(11):1979-1983. Epub 2016 Apr 15.

Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2015-208901DOI Listing
November 2016

Baricitinib in Patients with Refractory Rheumatoid Arthritis.

N Engl J Med 2016 Mar;374(13):1243-52

From the Stanford University Medical Center, Palo Alto, CA (M.C.G.); Albany Medical College, Albany, NY ( J.K.); Rheumazentrum Favoriten (O.Z.) and the Medical University of Vienna ( J.S.S.) - both in Vienna; East Penn Rheumatology, Bethlehem, PA (C.L.); Rheumatology Clinic, MAK-MED, Nadarzyn, Poland (M.K.); and Eli Lilly, Indianapolis (L.X., S.D.B., A.E.K., T.E.C., T.P.R., W.L.M., S.B., D.E.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1507247DOI Listing
March 2016

Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.

J Rheumatol 2016 Feb 15;43(2):298-306. Epub 2015 Dec 15.

From Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada; Immunology and Rheumatology, Stanford University, Palo Alto, California; Janssen Global Services LLC, Malvern, Pennsylvania, USA; Biostatistics, Janssen Research & Development LLC, Malvern; Biologics Clinical Pharmacology, and Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA; Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Rheumatology, Cabrini Medical Centre, Malvern, Australia; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.E.C. Keystone, MD, FRCP(C), Immunology and Rheumatology, University of Toronto and Mount Sinai Hospital; M.C. Genovese, MD, Immunology and Rheumatology, Stanford University; S. Hall, MBBS, FRACP, Rheumatology, Cabrini Medical Centre; S.C. Bae, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; C. Han, PhD, Janssen Global Services LLC; T.A. Gathany, MEd, Janssen Global Services LLC; S. Xu, MS, Biostatistics, Janssen Research & Development LLC; Y. Zhou, PhD, Biostatistics, Janssen Research & Development LLC; J.H. Leu, PhD, Biologics Clinical Pharmacology, Janssen Research & Development LLC; E.C. Hsia, MD, Immunology, Janssen Research & Development LLC, and Rheumatology, University of Pennsylvania School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.150712DOI Listing
February 2016

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.

J Rheumatol 2016 Feb 15;43(2):289-97. Epub 2015 Dec 15.

From the Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California; Eli Lilly and Company, Indianapolis, Indiana; Bristol-Myers Squibb, Princeton, New Jersey, USA.M.C. Genovese, MD, James W. Raitt Professor of Medicine, Co-Chief of Division of Immunology and Rheumatology, Stanford University School of Medicine; D.K. Braun, MD, Medical Fellow; Eli Lilly and Company; J.S. Erickson, PhD, Statistician, Eli Lilly and Company; P.Y. Berclaz, MD, Senior Medical Director, Eli Lilly and Company; M.P. Heffernan, MD, Senior Medical Director, Eli Lilly and Company; H. Carlier, MD, Senior Medical Advisor, Eli Lilly and Company, Indianapolis; S. Banerjee, MD, Bristol-Myers Squibb.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.140831DOI Listing
February 2016

Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.

J Rheumatol 2016 Feb 15;43(2):343-9. Epub 2016 Jan 15.

From the Swedish Medical Center; University of Washington, Seattle, Washington; Stanford University, Stanford; Amgen Inc., Thousand Oaks, California, USA.P.J. Mease, MD, Swedish Medical Center and University of Washington; M.C. Genovese, MD, Stanford University; A. Mutebi, PhD, Amgen Inc.; H.N. Viswanathan, PhD, Amgen Inc.; D. Chau, PharmD, Amgen Inc.; J. Feng, MS, formerly with Amgen Inc.; A. Nirula, MD, PhD, formerly with Amgen Inc.; N. Erondu, PhD, formerly with Amgen Inc.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.150182DOI Listing
February 2016

OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.

Ann Rheum Dis 2015 Dec 29;74(12):2123-9. Epub 2014 Jul 29.

Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2014-205361DOI Listing
December 2015

Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.

J Rheumatol 2015 Oct 1;42(10):1752-60. Epub 2015 Aug 1.

From the Division of Rheumatology, Stanford University, Palo Alto; Immunology, and Biostatistics, Janssen Research and Development LLC, La Jolla, California; Immunology, Janssen Research and Development, LLC, Spring House; Medical Affairs, Janssen Scientific Affairs LLC, Horsham, Pennsylvania; Quantitative Sciences, Janssen Research and Development LLC, Titusville, New Jersey, USA.M.C. Genovese, MD, Division of Rheumatology, Stanford University; E. Hsia, MD; S.M. Belkowski, PhD, Immunology, Janssen Research and Development LLC; C. Chien, PhD, Quantitative Sciences, Janssen Research and Development LLC; T. Masterson, MS; R.L. Thurmond, PhD; C.L. Manthey, PhD, Immunology, Janssen Research and Development LLC; X. Yan, PhD, Quantitative Sciences, Janssen Research and Development LLC; T. Ge, PhD, Biostatistics, Janssen Research and Development LLC; C. Franks, BS, Immunology, Janssen Research and Development LLC; A. Greenspan, MD, Medical Affairs, Janssen Scientific Affairs LLC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.141580DOI Listing
October 2015

Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O).

J Clin Rheumatol 2015 Aug;21(5):231-8

From the *Stanford University Medical Center, Palo Alto, CA; †NYU School of Medicine, New York, NY; ‡Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; §Private Practice, Memphis, TN; and ∥Eli Lilly and Company, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000276DOI Listing
August 2015

Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis.

J Rheumatol 2014 Nov 15;41(11):2104-13. Epub 2014 Aug 15.

From the University of Alberta, Edmonton, Alberta; Augurex Life Sciences Corp., North Vancouver, British Columbia; Mount Sinai Hospital, Toronto, Ontario, Canada; Quest Diagnostics Nichols Institute, San Juan Capistrano; Stanford University Medical Center, Palo Alto, California; Hospital for Special Surgery, New York, New York; Brigham and Women's Hospital, Boston, Massachusetts, USA; Vrije Universiteit University Medical Center; Academic Medical Center/University of Amsterdam; Jan van Breemen Research Institute, Reade organization, Amsterdam; the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; University of Cambridge, Cambridge; GlaxoSmithKline, Stevenage, UK.W.P. Maksymowych, MD, Professor of Medicine, University of Alberta; S.J. Naides, MD, Quest Diagnostics Nichols Institute; V. Bykerk, MD, Hospital for Special Surgery; K.A. Siminovitch, MD, Mount Sinai Hospital; D. van Schaardenburg, MD, Jan van Breemen Research Institute; M. Boers, MD, Vrije Universiteit University Medical Center; R. Landewé, MD, Academic Medical Center/University of Amsterdam; D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center; P-P. Tak, MD, Academic Medical Center/University of Amsterdam, University of Cambridge, GlaxoSmithKline; M.C. Genovese, MD, Stanford University Medical Center; M.E. Weinblatt, MD, Brigham and Women's Hospital; E.C. Keystone, MD, Mount Sinai Hospital; O.S. Zhukov, MS; R.W. Abolhosn, BS; J.M. Popov, MD, PhD, Quest Diagnostics Nichols Institute; K. Britsemmer, MD, Jan van Breemen Research Institute; A.W. van Kuijk, MD, Academic Medical Center/University of Amsterdam; A. Marotta, PhD, Augurex Life Sciences Corp.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.131446DOI Listing
November 2014

A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.

J Rheumatol 2014 Nov 15;41(11):2120-8. Epub 2014 Sep 15.

From Stanford University, Palo Alto, California, USA; Leiden University Medical Center, Leiden, The Netherlands; University of Toronto, Toronto, Ontario, Canada; Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina; Centre Hospitalier Régional, Orleans, France; University of California, San Diego, La Jolla, California; Austin Rheumatology Research PA, Austin, Texas; (formerly) AstraZeneca, Wilmington, Delaware, USA; AstraZeneca, Macclesfield, UK; Arthritis Associates, Orlando, Florida; Brigham and Women's Hospital, Boston, Massachusetts, USA.M.C. Genovese, MD, Stanford University; D.M. van der Heijde, MD, PhD, Leiden University Medical Center; E.C. Keystone, MD, University of Toronto; A.J. Spindler, MD, Centro Medico Privado de Reumatologia; C. Benhamou, MD, Centre Hospitalier Régional; A. Kavanaugh, MD, University of California, San Diego; E. Fudman, MD, Austin Rheumatology Research PA; K. Lampl, MD; C. O'Brien, MD, PhD, (formerly) AstraZeneca; E.L. Duffield, MSc, AstraZeneca, UK; J. Poiley, MD, Arthritis Associates; M.E. Weinblatt, MD, Brigham and Women's Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.140238DOI Listing
November 2014

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.

N Engl J Med 2014 Jun;370(24):2295-306

From the Swedish Medical Center and University of Washington, Seattle (P.J.M.); Oregon Health and Science University, Portland (A.D.); Stanford University, Palo Alto (M.C.G.), Desert Medical Advances, Palm Desert (M.W.G.), and Amgen, Thousand Oaks (R.N., J.Y.F., N.E., A.N.) - all in California; University of Rochester Medical Center, Rochester, NY (C.T.R.); and Laval University, Quebec, QC, Canada (A.D.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1315231DOI Listing
June 2014

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

J Rheumatol 2014 Apr 1;41(4):629-39. Epub 2014 Mar 1.

From Stanford University, Palo Alto, California, USA; Universidad Autónoma de Chihuahua, Chihuahua; Unidad Reumatologica Las Americas S.C.P., Mérida, Mexico; Instituto De Ginecologia Y Reproduccion, Lima, Peru; Organización Médica de Investigación, Buenos Aires, Argentina; Pontificial Catholic University School of Medicine, Porto Alegre, Brazil; Physician Research Collaboration, Lincoln, Nebraska, USA; University of Queensland, Brisbane, Queensland, Australia; Centro De Especialidades Médicas/Universidad Marista, Mérida, Mexico; Box Arthritis and Rheumatology of the Carolinas, Charlotte, North Carolina; Low Country Rheumatology, Charleston, South Carolina, USA; Institute of Rheumatology, Moscow, Russia; Service et Pôle de Rhumatologie, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium; Bristol-Myers Squibb, Princeton, New Jersey, USA; and Schlosspark-Klinik, Teaching Hospital of the Charité University Medicine Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.130112
Publisher Site
http://dx.doi.org/10.3899/jrheum.130112DOI Listing
April 2014

One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.

J Rheumatol 2014 Mar 15;41(3):414-21. Epub 2014 Jan 15.

From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.130637DOI Listing
March 2014

Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.

J Clin Rheumatol 2014 Jan;20(1):1-10

From the *Allegheny Singer Research Institute, West Penn Allegheny Health System; †Temple University School of Medicine-Pittsburgh Campus, Pittsburgh, PA; ‡Janssen Research & Development, LLC, Spring House, PA; §University of Pennsylvania School of Medicine, Philadelphia, PA; ∥Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom; ¶Department of Neurology and Stroke Center, Hôpital Bichat, Paris, France; #Metroplex Clinical Research Center, Dallas, TX; **Stanford University, Palo Alto, CA; and ††Mayo Clinic College of Medicine, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000053DOI Listing
January 2014

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.

Ann Rheum Dis 2013 Sep 25;72(9):1461-8. Epub 2012 Dec 25.

Division of Immunology and Rheumatology, Stanford University, , Palo Alto, CA 94304, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2012-202775DOI Listing
September 2013

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.

Ann Rheum Dis 2013 Sep 18;72(9):1453-60. Epub 2013 Apr 18.

Division of Immunology and Rheumatology, Stanford University Medical Center, , Palo Alto, California 94304, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2012-202864DOI Listing
September 2013

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.

J Rheumatol 2013 Jul 15;40(7):1097-103. Epub 2013 May 15.

Immunology department, University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.120584DOI Listing
July 2013

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.

J Rheumatol 2013 May 1;40(5):579-89. Epub 2013 Apr 1.

Division of Rheumatology, Los Angeles County + University of Southern California Medical Center and University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA.

View Article

Download full-text PDF

Source
http://www.jrheum.org/cgi/doi/10.3899/jrheum.120886
Publisher Site
http://dx.doi.org/10.3899/jrheum.120886DOI Listing
May 2013

Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.

Arthritis Care Res (Hoboken) 2013 Mar;65(3):362-71

Division of Rheumatology and Immunology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.21847DOI Listing
March 2013

Effects of sclerostin antibody on healing of a non-critical size femoral bone defect.

J Orthop Res 2013 Jan 8;31(1):155-63. Epub 2012 Aug 8.

Department of Orthopaedic Surgery, Stanford University, 450 Broadway Street, Mail Code 6342 Redwood City, Stanford, California 94063, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jor.22186DOI Listing
January 2013

IL-17 receptor and its functional significance in psoriatic arthritis.

Mol Cell Biochem 2012 Jan 6;359(1-2):419-29. Epub 2011 Sep 6.

Division of Rheumatology, Allergy & Clinical Immunology, University of California Davis School of Medicine & VA Medical Center Sacramento, 1911 Geneva Place, Davis, CA 95618, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11010-011-1036-6DOI Listing
January 2012

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial.

Ann Rheum Dis 2011 Nov 21;70(11):1968-74. Epub 2011 Jul 21.

Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK.

View Article

Download full-text PDF

Source
http://ard.bmj.com/cgi/doi/10.1136/ard.2010.146068
Publisher Site
http://dx.doi.org/10.1136/ard.2010.146068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184239PMC
November 2011

Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis.

Arthritis Care Res (Hoboken) 2011 Mar 18;63(3):373-82. Epub 2010 Oct 18.

Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.20372DOI Listing
March 2011

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

N Engl J Med 2010 Sep 22;363(14):1303-12. Epub 2010 Sep 22.

Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1000500DOI Listing
September 2010

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study.

Ann Rheum Dis 2010 Jun 5;69(6):1129-35. Epub 2010 May 5.

University of Toronto and Mount Sinai Hospital, 60 Murray Street, 2nd Floor, Room 2-006, Toronto, Ontario M5G 1X5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ard.2009.116319DOI Listing
June 2010

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.

J Rheumatol 2009 Jul 15;36(7):1429-41. Epub 2009 Apr 15.

Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine,University of Leeds; NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.081018DOI Listing
July 2009

Inhibition of p38: has the fat lady sung?

Authors:
Mark C Genovese

Arthritis Rheum 2009 Feb;60(2):317-20

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.24264DOI Listing
February 2009